Browse News
Filter News
Found 722,831 articles
-
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
-
Enanta Pharmaceuticals' attempt to find an effective treatment for respiratory syncytial virus (RSV) met a roadblock after its candidate failed to meet the primary endpoint in Phase II.
-
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
-
Spruce Biosciences is developing what could be the first new therapy treating congenital adrenal hyperplasia (CAH) since the 1960s, and a new therapy for women with polycystic ovary syndrome.
-
GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.
-
Pfizer, Sarepta Therapeutics, Genethon and Solid Biosciences are working on gene therapies for Duchenne Muscular Dystrophy. Now, the four companies have teamed up.
-
Maxwell Serowoky has observed an increase in Sonic Hedgehog (Shh) gene activity during rib bone recovery, expanding the gene’s function beyond the known role of embryogenesis.
-
In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
-
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
5/19/2022
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc.
-
Biora Therapeutics Announces New Patents for Targeted Therapeutics PlatformMarks 29 Patents Worldwide Directed to Biora’s Device Localization Technology
5/19/2022
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery System (DDS) platform under development.
-
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
5/19/2022
This acquisition solidifies CellCarta's leadership position in proteomics services with a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-oncology targets.
-
AIkido Pharma Announces Company Commitment to Board Diversity
5/19/2022
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the Company's commitment to complying with the NASDAQ listing requirements on board diversity by August 1, 2022.
-
MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO
5/19/2022
MAIA Biotechnology, Inc, a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the company has established two wholly-owned subsidiaries in Romania and Australia to broaden and accelerate its global development plan for THIO.
-
Equifund Oversubscribes Kleiner Device Labs Reg-CF Offering
5/19/2022
Equifund ( https://equifund.com ), a private market investment platform that delivers vetted, early-stage investment opportunities to the public, announces it successfully oversubscribed a Reg-CF offering for Kleiner Device Labs.
-
Calliditas receives positive CHMP opinion in IgA nephropathy
5/19/2022
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo TM.
-
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
5/19/2022
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107.
-
Occlutech Signs Exclusive US Distribution Agreement with B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc.
5/19/2022
Occlutech Holding AG Occlutech Holding AG (Occlutech), a leading specialist provider of minimally invasive structural heart implants, has signed an exclusive distribution agreement with B. Braun Interventional Systems Inc. (BIS) as an important next step in Occlutech's commercial development in the US.
-
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
5/19/2022
AcelRx Pharmaceuticals, Inc. today reported that the U.S. Food and Drug Administration (FDA) has recently modified the DSUVIA Risk Evaluation and Mitigation Strategies (REMS) requirements with respect to healthcare setting audits.
-
Thermo Fisher Scientific and LabShares Partner to Support Emerging Boston Biotechs
5/19/2022
To support the Greater Boston biotech ecosystem, Thermo Fisher Scientific is joining forces with biotech incubator LabShares Newton to provide instruments, lab equipment and consumables to help early-stage life sciences companies accelerate their
-
Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years
5/19/2022
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options.